Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes

Blake A. Niccum; Jonathan G. Stine; Javelle A. Wynter; Virginia Kelly; Stephen H. Caldwell; Neeral L. Shah

doi:10.2337/cd18-0112

Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes

Blake A. Niccum
, Jonathan G. Stine
, Javelle A. Wynter
, Virginia Kelly
, Stephen H. Caldwell
, Neeral L. Shah

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.

Original language	English (US)
Pages (from-to)	40-46
Number of pages	7
Journal	Clinical Diabetes
Volume	38
Issue number	1
DOIs	https://doi.org/10.2337/cd18-0112
State	Published - Jan 2021

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2337/cd18-0112

Cite this

@article{7db732c209c64a6093ae255d1a7cb28d,

title = "Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes",

abstract = "Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.",

author = "Niccum, \{Blake A.\} and Stine, \{Jonathan G.\} and Wynter, \{Javelle A.\} and Virginia Kelly and Caldwell, \{Stephen H.\} and Shah, \{Neeral L.\}",

note = "Publisher Copyright: {\textcopyright} 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.",

year = "2021",

month = jan,

doi = "10.2337/cd18-0112",

language = "English (US)",

volume = "38",

pages = "40--46",

journal = "Clinical Diabetes",

issn = "0891-8929",

publisher = "American Diabetes Association Inc.",

number = "1",

}

TY - JOUR

T1 - Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes

AU - Niccum, Blake A.

AU - Stine, Jonathan G.

AU - Wynter, Javelle A.

AU - Kelly, Virginia

AU - Caldwell, Stephen H.

AU - Shah, Neeral L.

N1 - Publisher Copyright: © 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.

PY - 2021/1

Y1 - 2021/1

N2 - Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.

AB - Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.

UR - https://www.scopus.com/pages/publications/85104113505

UR - https://www.scopus.com/pages/publications/85104113505#tab=citedBy

U2 - 10.2337/cd18-0112

DO - 10.2337/cd18-0112

M3 - Article

C2 - 31975750

AN - SCOPUS:85104113505

SN - 0891-8929

VL - 38

SP - 40

EP - 46

JO - Clinical Diabetes

JF - Clinical Diabetes

IS - 1

ER -

Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this